New England Journal of Medicine· 2020Q1· Clinical trial
Dexamethasone in Hospitalized Patients with Covid-19
- 10,118citations
- Q1SCImago
- 2020year
Short summary
Dexamethasone significantly reduced 28-day mortality by 17% (rate ratio 0.83) in hospitalized COVID-19 patients. The benefit was most pronounced in patients requiring mechanical ventilation or oxygen support.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Infectious Diseases
Infectious DiseasesMedicine